Ezetimibe
Lipid-regulating drugs | Cardiovascular System
Items (National)
4.9M
NHS Cost
£26.8M
Practices
6,823
Avg per Practice
711
Overview
Ezetimibe is prescribed by 6,823 GP practices across England. In the last 12 months, 4,853,954 items were prescribed at a total cost of £26,792,468 to the NHS. It is classified under BNF Chapter Cardiovascular System, Section Lipid-regulating drugs.
Monthly Prescribing Trend
Jun 2026
357,827
Jun 2026
343,385
Jun 2026
384,662
Jun 2026
382,629
Jun 2026
379,852
Jun 2026
412,498
Jun 2026
405,699
Jun 2026
426,971
Jun 2026
443,456
Jun 2026
409,441
Jun 2026
444,700
Jun 2026
458,145
Prescribing by Area
| Area | Items | Practices | Avg/Practice | vs National |
|---|---|---|---|---|
| NE | 197.1K | 139 | 1,418 | +99.4% ▲ |
| B | 193.6K | 266 | 728 | +2.3% ▲ |
| S | 149.8K | 169 | 887 | +24.6% ▲ |
| LE | 132.8K | 125 | 1,062 | +49.3% ▲ |
| M | 121.6K | 173 | 703 | -1.2% vs avg |
| NG | 104.3K | 137 | 761 | +7.0% ▲ |
| LS | 101.8K | 91 | 1,119 | +57.3% ▲ |
| PE | 99.1K | 92 | 1,077 | +51.4% ▲ |
| BS | 95.2K | 79 | 1,206 | +69.5% ▲ |
| DN | 86.0K | 88 | 977 | +37.3% ▲ |
| TS | 85.5K | 72 | 1,188 | +67.0% ▲ |
| CV | 82.5K | 110 | 750 | +5.4% ▲ |
| L | 82.1K | 144 | 570 | -19.8% ▼ |
| BN | 78.3K | 77 | 1,017 | +42.9% ▲ |
| SW | 70.2K | 115 | 610 | -14.2% ▼ |
| ST | 67.4K | 84 | 803 | +12.8% ▲ |
| W | 66.9K | 97 | 690 | -3.1% ▼ |
| NN | 63.9K | 66 | 968 | +36.0% ▲ |
| PO | 63.5K | 63 | 1,008 | +41.7% ▲ |
| E | 62.8K | 139 | 452 | -36.5% ▼ |
Top Prescribing Practices
| Practice | Items |
|---|---|
| VALENS MEDICAL PARTNERSHIP | 9,609 |
| BEACON MEDICAL PRACTICE | 6,778 |
| HEALTH AND BEYOND | 6,589 |
BNF Classification
- Chapter: Cardiovascular System
- Section: Lipid-regulating drugs
- Paragraph: Lipid-regulating drugs
Related drugs in this section
Explore More
Data sourced from NHSBSA English Prescribing Dataset, CQC, and GP Patient Survey. Prescribing data does not indicate quality of care. Higher prescribing rates may reflect patient demographics. Always consult your GP for medical advice.